scispace - formally typeset
P

Paolo Fanti

Researcher at University of Texas Health Science Center at San Antonio

Publications -  62
Citations -  3442

Paolo Fanti is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Parathyroid hormone & Bone disease. The author has an hindex of 29, co-authored 58 publications receiving 3144 citations. Previous affiliations of Paolo Fanti include University of Oklahoma & University of Texas at Austin.

Papers
More filters
Journal ArticleDOI

The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach.

TL;DR: The purpose of this review is to examine the mechanisms that link oxidative stress to micro- and macrovascular complications in subjects with type 2 diabetes and to consider the therapeutic opportunities that are presented by currently used therapeutic agents which possess antioxidant properties as well as new potential antioxidant substances.
Journal ArticleDOI

The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats.

TL;DR: This study shows that GEN reduces both trabecular and compact bone loss after ovariectomy and that this protective effect differs from that of estrogen, since it depends on stimulation of bone formation rather than on suppression of bone resorption.
Journal ArticleDOI

Analysis of GSH and GSSG after derivatization with N -ethylmaleimide

TL;DR: This procedure can assay GSH and GSSG in blood and other tissues in 30 min or less and can be prevented by derivatizing GSH with the alkylating agent N-ethylmaleimide (NEM) to form GS-NEM before acid deproteination.
Journal ArticleDOI

In Vitro and In Vivo Effects of Genistein on Murine Alveolar Macrophage TNFα Production

TL;DR: In vitro incubation with genistein completely inhibited LPS-induced TNFα production by alveolar macrophages (AM) from BALB/c mice and was associated with a decrease in BAL WBC count post-LPS.
Journal ArticleDOI

Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes

TL;DR: The data indicate that pharmacological inhibition of Nox1/4 affords broad renoprotection in mice with preexisting diabetes and established kidney disease and identifies GKT137831 as a promising compound for the treatment of DN in type 1 diabetes.